KIT and cancer: In contrast, the lack of synergy between the IM and PDS-0330 observed in GIST430 cells may be due to the absence of CLDN1 in these particular cancer cells, which acquired resistance to IM via other molecular mechanisms, underlying beyond the CLDN1 pathway and including secondary KIT mutations and, potentially, the development of EMT.